David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Nathan Hale Fowler, MD, of MD Anderson Cancer Center, discusses a multicenter trial in which ibrutinib plus rituximab was administered to treatment-naive patients with follicular lymphoma (Abstract 470).

Symptom Management

Alok A. Khorana, MD

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Alok A. Khorana, MD, of the Cleveland Clinic, discusses study results on the use of dalteparin for thromboprophylaxis in cancer patients at high risk for the condition (Abstract 427).

Leukemia

Richard M. Stone, MD

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Richard M. Stone, MD, of the Dana-Farber Cancer Institute, discusses this international prospective study on the survival impact of midostaurin, a multikinase inhibitor, in newly diagnosed acute myeloid leukemia with FLT3 mutations (Abstract 6).

Leukemia

Julie Vose, MD, MBA

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses a retrospective analysis of data on the overall survival of patients with acute lymphoblastic leukemia when initial therapy is given in academic hospitals vs nonacademic hospitals (Abstract 268).

Leukemia

Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses a late-breaking abstract on the superiority of this three-drug combination compared to bendamustine and rituximab alone in patients with relapsed/refractory chronic lymphocytic leukemia (Abstract LBA5).

Jul

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

Nathan Hale Fowler, MD, on Follicular Lymphoma: Ibrutinib Plus Rituximab Study Results

Alok A. Khorana, MD, on Preventing Venous Thromboembolism

Richard M. Stone, MD, on AML: Results of the RATIFY Trial

Julie Vose, MD, MBA, on ALL Overall Survival: Academic vs Nonacademic Hospitals

Andrew D. Zelenetz, MD, PhD, on CLL: Idelalisib Plus Bendamustine and Rituximab

GLP-1 Receptor Agonists Linked to Lower Colorectal Cancer Risk in Patients With IBD

Intraoperative Margin Assessment With Specimen PET/CT Imaging in Early Breast Cancer

No Survival Benefit From Chemoradiotherapy After D2 Gastrectomy in Gastric Cancer

All-Oral Combination of Revumenib, Decitabine/Cedazuridine, and Venetoclax for Relapsed or Refractory AML

Investigators Identify Resistance Mechanism to Tagraxofusp Among Patients With BPDCN